Tag: ChAdOx1

1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. 2. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination. 2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%. Evidence Rating...
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The neutralizing titer of the vaccinated individuals was nine times lower against B.1.1.7 than the non-B.1.1.7 (Victoria) strain in vitro. Evidence Rating Level: 1 (Excellent) Study Rundown: As vaccines are distributed worldwide, concern...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there were no hospital admissions for COVID-19 in the ChAdOx1-nCoV-19 group.  Evidence Rating Level: 1 (Excellent) Study Rundown: At the time of this publication, the COVID-19 pandemic continues to burden healthcare systems...